Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Sees FY Unaudited Net Profit Attributable RMB35 Million To RMB52 Million

Like
Comment
Favorite

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Sees FY Unaudited Net Profit Attributable RMB35 Million To RMB52 Million

Reuters01-17

Jan 17 (Reuters) - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd <688505.SS>::
*SEES UNAUDITED NET PROFIT ATTRIBUTABLE RMB35 MILLION TO RMB52 MILLION FOR YEAR
*Further company coverage: 688505.SS
* ((Reuters.Briefs@thomsonreuters.com;;))

((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))
Source Date/Time = 17-JAN-202515:23:35 GMT

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

No comments yet

抱歉，当前请求异常(-1)

7x24

All

07:14
Humana Ab : Kepler Cheuvreux Raises Target Price to SEK 50 From SEK 44
07:13
Banks , Tech , Industrials , Energy Basic Resources Top Sectoral Gainers in Europe, up 9-10%
07:13
Acomo Nv : Kepler Cheuvreux Raises Target Price to EUR 25 From EUR 23.2
07:13
Shares in Car Suppliers Opmobility up 10.9%, Valeo up 15%, and Michelin up 5.2%
07:12
Nordic Steelmakers Ssab, Outokumpu Shares up Between 7-11% in Morning Trade

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2504788160?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-01-17 23:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2504788160","market":"us","top_or_hot":-1,"title":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Sees FY Unaudited Net Profit Attributable RMB35 Million To RMB52 Million","media":"Reuters","content":"<html><body>Jan 17 (Reuters) - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd &lt;688505.SS&gt;::<br/>*SEES  UNAUDITED NET PROFIT ATTRIBUTABLE RMB35 MILLION TO RMB52 MILLION FOR YEAR<br/>*Further company coverage: 688505.SS<br/>* ((Reuters.Briefs@thomsonreuters.com;;))<br/><br/>  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))<br/>  Source Date/Time = 17-JAN-202515:23:35 GMT</body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Sees FY Unaudited Net Profit Attributable RMB35 Million To RMB52 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShanghai Fudan-Zhangjiang Bio-Pharmaceutical Sees FY Unaudited Net Profit Attributable RMB35 Million To RMB52 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-01-17 23:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body>Jan 17 (Reuters) - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd &lt;688505.SS&gt;::<br/>*SEES  UNAUDITED NET PROFIT ATTRIBUTABLE RMB35 MILLION TO RMB52 MILLION FOR YEAR<br/>*Further company coverage: 688505.SS<br/>* ((Reuters.Briefs@thomsonreuters.com;;))<br/><br/>  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))<br/>  Source Date/Time = 17-JAN-202515:23:35 GMT</body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688505","symbol_name":"复旦张江","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250117:nRSD4Tfz46:1","article_id":"2504788160","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2504788160","pubTimestamp":1737128166,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Jan 17 (Reuters) - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd <688505.SS>::*SEES  UNAUDITED NET PROFIT ATTRIBUTABLE RMB35 MILLION TO RMB52 MILLION FOR YEAR*Further company coverage: 688505.SS","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688505":"复旦张江","BK0239":"医药制造"},"translate_title":"上海复旦张江生物制药预计财年未经审计归属净利润人民币3500万元至人民币5200万元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688505":0.9},"content_text":"Jan 17 (Reuters) - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd <688505.SS>::*SEES  UNAUDITED NET PROFIT ATTRIBUTABLE RMB35 MILLION TO RMB52 MILLION FOR YEAR*Further company coverage: 688505.SS* ((Reuters.Briefs@thomsonreuters.com;;))  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 17-JAN-202515:23:35 GMT","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}